Skip to Content

Etretinate Disease Interactions

There are 4 disease interactions with etretinate:

Major

Retinoids (Includes Etretinate) ↔ Intracranial Hypertension

Severe Potential Hazard, High plausibility

Applies to: Intracranial Hypertension

The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension). Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances. Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist. If the diagnosis is confirmed, the retinoid should be discontinued permanently.

References

  1. "Product Information. Soriatane (acitretin)." Roche Laboratories, Nutley, NJ.
  2. "Product Information. Accutane (isotretinoin)." Roche Laboratories, Nutley, NJ.
Major

Retinoids (Includes Etretinate) ↔ Psychiatric Disorders

Severe Potential Hazard, Low plausibility

Applies to: Psychosis, Depression

The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation. Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression. In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.

References

  1. "Product Information. Soriatane (acitretin)." Roche Laboratories, Nutley, NJ.
  2. "Product Information. Accutane (isotretinoin)." Roche Laboratories, Nutley, NJ.
Moderate

Retinoids (Includes Etretinate) ↔ Elevated Serum Triglycerides

Moderate Potential Hazard, High plausibility

Applies to: Obesity, Diabetes Mellitus, Alcoholism, Hyperlipidemia

The use of retinoids is associated with elevations in serum triglycerides and cholesterol, and decreases in HDL. In addition to cardiovascular risks, elevation of serum triglycerides to greater than 800 mg/dL has been associated with fatal fulminant pancreatitis. Patients at increased risk for developing hypertriglyceridemia during retinoid therapy include those with diabetes mellitus, obesity, high alcohol consumption, or a family history of these conditions. Blood lipid determinations should be performed prior to initiation of therapy and at 1- to 2- week intervals until the lipid response to the drug is established (usually 4 to 8 weeks). Patients with preexisting hyperlipidemia may require closer monitoring during retinoid therapy, and adjustments made accordingly in their lipid-lowering regimen.

References

  1. "Product Information. Accutane (isotretinoin)." Roche Laboratories, Nutley, NJ.
  2. "Product Information. Soriatane (acitretin)." Roche Laboratories, Nutley, NJ.
Moderate

Retinoids (Includes Etretinate) ↔ Liver Disease

Moderate Potential Hazard, High plausibility

Applies to: Liver Disease

The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis. Therapy with retinoids should be administered cautiously in patients with liver disease. Monitoring liver enzymes is recommended in these patients.

References

  1. "Product Information. Soriatane (acitretin)." Roche Laboratories, Nutley, NJ.
  2. "Product Information. Accutane (isotretinoin)." Roche Laboratories, Nutley, NJ.

etretinate drug Interactions

There are 55 drug interactions with etretinate

etretinate alcohol/food Interactions

There are 2 alcohol/food interactions with etretinate

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide